Table 5 Summary of adverse events and serious adverse events (all enrolled participants)
Number of individuals (N = 36) | |
|---|---|
Adverse events | - |
Total | 25 (69.4%) |
Mild | 23 (63.9%) |
Moderate | 15 (41.7%) |
Severe | 5 (13.9%) |
Most common adverse events experienced by > 5% of participants | - |
Rhinitis | 8 (22.2%) |
Diarrhoea | 7 (19.4%) |
Pyrexia | 6 (16.7%) |
Nasopharyngitis | 5 (13.9%) |
Bronchitis | 3 (8.3%) |
Gastroenteritis | 2 (5.6%) |
Cough | 2 (5.6%) |
Vomiting | 2 (5.6%) |
Hepatomegaly | 2 (5.6%) |
Pharyngitis | 2 (5.6%) |
Skin infection | 2 (5.6%) |
Pain in extremities | 2 (5.6%) |
Headache | 2 (5.6%) |
Serious adverse events | |
Total | 3 (8.3%) |
Wound infection | 2 (5.6%) |
Streptococcus infection | 1 (2.8%) |
Scarlet fever | 1 (2.8%) |
EBV infection | 1 (2.8%) |
Discontinuations owing to adverse events | 0 (0.0%) |